Clinical trial
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With…
NCT00003847 · Vertex Pharmaceuticals Incorporated, Industry · Terminated
Key facts
| NCT number | NCT00003847 |
|---|---|
| Title | VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer |
| Official title | A Phase II Study of the Safety, Efficacy and Pharmacokinetics of VX-710 in Combination With Doxorubicin and Vincristine in Patients With Small Cell Lung Cancer (SCLC) |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | biricodar dicitrate, doxorubicin hydrochloride, vincristine sulfate |
| Enrollment | 36 |
| Start date | Dec 1, 1998 |
| Primary completion | Feb 1, 2001 |
| First posted | Jun 16, 2004 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: